Stock Events

Stock Events

Scandion Oncology A/S 

SEK0
3
-SEK0-39.71% Friday 15:29

Statistics

Day High
0.01
Day Low
0
52W High
0.18
52W Low
0
Volume
29,309,363
Avg. Volume
8,750,569
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

29MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.88
-0.55
-0.21
0.12
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-56.05MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SCOL.ST. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. develops oncology drugs that directly compete in the cancer treatment market, overlapping with Scandion Oncology's focus.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is involved in developing cancer therapies, potentially competing with Scandion Oncology's drug development pipeline.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad portfolio of oncology drugs that could compete with treatments being developed by Scandion Oncology.
Novartis
NVS
Mkt Cap237.61B
Novartis AG focuses on innovative healthcare solutions including oncology, which competes with Scandion Oncology's cancer treatment research.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG specializes in biopharmaceuticals, including oncology, which is a direct market competitor to Scandion Oncology.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a strong focus on the development of cancer drugs, competing in the same space as Scandion Oncology.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. develops therapeutic solutions in oncology, competing with Scandion Oncology's approach to cancer treatment.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. operates in the oncology sector, providing competitive pressure to Scandion Oncology's market.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company produces oncology drugs, which could compete with the cancer treatments developed by Scandion Oncology.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biopharmaceuticals, including oncology, competing with Scandion Oncology's research and products.

About

Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.
Show more...
CEO
Mr. Jan Stenvang M.S., Ph.D.
Employees
4
Country
DK
ISIN
DK0061031895

Listings

0 Comments

Share your thoughts

FAQ

What is Scandion Oncology A/S stock price today?▼
The current price of SCOL.ST is SEK0 SEK — it has decreased by -39.71% in the past 24 hours. Watch Scandion Oncology A/S stock price performance more closely on the chart.
What is Scandion Oncology A/S stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Scandion Oncology A/S stocks are traded under the ticker SCOL.ST.
Is Scandion Oncology A/S stock price growing?▼
SCOL.ST stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Scandion Oncology A/S has showed a -59% decrease.
What is Scandion Oncology A/S revenue for the last year?▼
Scandion Oncology A/S revenue for the last year amounts to 0 SEK.
What is Scandion Oncology A/S net income for the last year?▼
SCOL.ST net income for the last year is -56.05M SEK.
How many employees does Scandion Oncology A/S have?▼
As of April 01, 2026, the company has 4 employees.
In which sector is Scandion Oncology A/S located?▼
Scandion Oncology A/S operates in the Health Care sector.
When did Scandion Oncology A/S complete a stock split?▼
Scandion Oncology A/S has not had any recent stock splits.
Where is Scandion Oncology A/S headquartered?▼
Scandion Oncology A/S is headquartered in Copenhagen, DK.